MARKET

ALPX

ALPX

ALOPEXX INC
NASDAQ
5.00
0.00
0.00%
Suspension
OPEN
5.00
PREV CLOSE
5.00
HIGH
5.00
LOW
5.00
VOLUME
0
TURNOVER
--
52 WEEK HIGH
5.00
52 WEEK LOW
5.00
MARKET CAP
39.26M
P/E (TTM)
--
1D
5D
1M
3M
1Y
5Y
ALOPEXX INC: [Amend]General form for registration of securities under the Securities Act of 1933
Press release · 12/27/2023 14:14
About ALPX
Alopexx Inc. is a clinical-stage biotechnology company. The Company is engaged in developing novel immune therapeutics for the prevention, treatment, and mitigation of bacterial, fungal, and parasitic infections that express the antigenic target poly N-acetyl glucosamine (PNAG). The Company's immune therapeutics target the conserved microbial surface polysaccharide poly N-acetyl glucosamine (PNAG). The Company's vaccine candidate, Vaccine AV0328, is a synthetic PNAG vaccine. It induces antibodies that are capable of killing a wide range of PNAG-expressing pathogens. AV0328 be developed as a complement to Streptococcus pneumonia vaccines (Prevnar, Pneumovax, and Vaxneuvance). AV0328 could protect against many of approximately 80 serotypes. Its Monoclonal antibody F598 is a human monoclonal antibody. It will not replace antibiotics but will instead complement and augment their efficacy and by doing so reduce the development of antibiotic-resistant organisms.

Webull offers Alopexx Inc stock information, including NASDAQ: ALPX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALPX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALPX stock methods without spending real money on the virtual paper trading platform.